Sara Durland-Busbice, n/a

Boehringer Ingelheim Pharmaceuticals Inc
Ridgefield, Connecticut, United States

Presentation(s):

• Paper 19 - A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 IN PATIENTS WITH SOLID TUMORS, INCLUDING ADVANCED/METASTATIC LIPOSARCOMA

  Thursday, November 17, 2022
  1:16 PM – 1:24 PM